The adverse effects of hypothyroidism and hyperthyroidism during pregnancy

Document Type: Review

Author

Department of Gynecology, Mashhad university of Medical Sciences, Mashhad, Iran.

Abstract

Due to the important role of thyroid disorders on reproductive health of the women of childbearing age, pregnancy outcome, fetal health, and neurodevelopment of the infant, providing comprehensive assessment of the treatments used for preventing hyperthyroidism and hypothyroidism seems to be essential. Therefore, evaluating the efficacy of different treatments of the thyroid disorders would be beneficial in better managing and controlling the disease during pregnancy. Hypothyroidism (a deficiency of thyroid hormone) is a common thyroid disorder, which might increase the incidence rate of miscarriage, pre-eclampsia, placental abruption, and preterm delivery. Hyperthyroidism, which is not a common disorder during the pregnancy not only leads to similar adverse effects as hypothyroidism but also can result in stillbirth and intrauterine growth restriction. Levothyroxine is the preferred treatment of hypothyroidism and the only drug therapy recommended for treating hyperthyroidism during pregnancy. In this study, we aimed to briefly review the adverse effects of hyperthyroidism and hypothyroidism during pregnancy and review the effects of recent suggested treatments for controlling thyroid disorders on pregnancy outcomes.

Keywords


Introduction
Thyroid hormones
The concentration of the thyroid hormone can affect the heart, connective tissue, metabolite rate, glucose metabolism, protein catabolism, cholesterol level, etc. These hormones can also affect the growth and development; specifically the development of the cortex and ganglia of the brain. Iodine obtained from the diet is utilized by thyroid gland for producing thyroid hormones including thyroxine (T4) and triiodothyronine (T3) and the rest is excreted in the urine. The thyroid hormone production is controlled by the thyrotropin (thyroid-stimulating hormone, TSH) secreted from pituitary, which is regulated by hypothalamus through generating thyrotropin-releasing hormone (TRH) (1). Thyroid hormones are among the essential hormones for the normal metabolism, growth, development, and maturation. Major part of serum transporting of the endogenous T3 and T4 is done by binding to the thyroxine-binding globulin, transthyretin and albumin. During pregnancy, the increase of serum concentration of these binding proteins leads to the rise of the T4 concentration rate. Thyroid physiology would be altered during pregnancy due to hormonal changes. After a few weeks, the thyroid-binding globulin (TBG) will increase and reach to 2-3 fold higher concentration than its pre-pregnancy levels. The concentration of T4 and T3 would increase especially between 6 and 12 weeks of pregnancy as the consequences of TBG rise (2).
Literature review
Thyroid diseases
Pregnancy is among the possible risk factors of the thyroid dysfunction. Normal thyroid function is essential for continuing normal reproduction. Hormonal changes such as increase in the estrogen level during pregnancy might lead to the significant changes of the thyroid function and iodine metabolism that eventually lead to higher obstetric complications in some cases (3).
In some pregnancy cases, normal physiological changes of the thyroid and nonspecific symptoms during congestion can inhibit thyroid disorder detection.
The prevalence of the thyroid dysfunction during pregnancy is estimated to be higher in regions with severe iodine deficiency compared with iodine-sufficient areas, which necessitates the thyroid function controlling in all the pregnant women to identify the cases with thyroid disorders (4). The prevalence of thyroid dysfunctions has been estimated to be almost 5% of all the pregnant women and 5 -10 % among the women at childbearing age.
Thyroid diseases as the second most common disorder after the diabetes mellitus comprise hyperthyroidism, hypothyroidism, chronic autoimmune thyroiditis, and hypothyroxinemia.
Habitual abortion, preterm labor, fetal death, retardation, congenital malformations, bleeding and depression after birth, anemia, cardiac disorder, and increased risk of maternal morbidity and mortality are various consequences of thyroid dysfunction during pregnancy (5,6).

Hyperthyroidism
Hyperthyroidism can be defined as the overproduction of the thyroid hormones (T4 orT3) with the prevalence rate of approximately 1% to 4% in the general population. It represents with a wide variety of the symptoms, which are different between patients such as anxiousness, tachycardia, atrial fibrillation, increased heat sensitivity, perspiration, skin changes, loss of weight, insulin resistance, fatigue, and shivering. The major cause of the hyperthyroidism, almost in 85% of the cases, is proposed to be the autoimmune Graves disease, which might be diagnosed through symptoms such as heat intolerance, enlargement of thyroid gland, increased T4, presence of thyroid autoantibodies, fetal tachycardia and cardiac failure, and fetal retardation (7). Graves disease has higher prevalence in women than men; specifically in women at reproductive age (20 to 40 years old) (8). Thyroid toxic adenoma, toxic nodular goiter, thyroid inflammation, gestational trophoblastic disease, struma ovarii and thyrotropin receptor (TSHR) activation are other possible conditions, which might lead to the occurrence of hyperthyroidism (9-11).
Radioactive iodine uptake (RAIU) test is a diagnostic method of thyroid disorders especially hyperthyroidism, which is not appropriate to be used during pregnancy. Increased risk of several complications such as congestive heart failure, thyroid crisis, placental abruption, pre-eclampsia, miscarriage, stillbirth, premature birth, and intrauterine growth restriction (IUGR) has been illustrated as the consequences of hyperthyroidism during pregnancy. In order to treat the thyroid diseases of pregnant mother and prevent the incidence of the further complications, diagnosis and controlling of the thyroid status of the pregnant mother and the fetus is important early in the pregnancy.
Although radioactive iodine (radioiodine) therapy, antithyroid medications, and surgery are different types of hyperthyroidism treatment, only pharmacotherapy is suggested to be appropriate for the pregnant women. By performing radioiodine therapy, the maternal hyperthyroidism would be treated as a result of destroyed thyroid glands, which can lead to the neonatal hypothyroidism (12).
Thionamides, propylthiouracil (PTU), methimazole and carbimazole are different medications that can be used for treating the hyperthyroidism. Thionamides and methimazole act by blocking the enzyme thyroperoxidase, which leads to the inhibition of thyroid hormone synthesis in thyroid gland (8). Various side effects have been identified by using hyperthyroidism-treating drugs during pregnancy. Pruritus, rash, hives, swelling, fever, nausea, vomiting, granulopenia, septicemia, vasculitis, and liver dysfunction have been mentioned as the adverse effects of pharmacotherapy for treating hyperthyroidism (8).
In pregnancies with hyperthyroidism incidence, methiamazole and thionamides are proposed drugs, which might lead to fetal birth abnormalities and maternal liver injuries, respectively (13).
Although the lower doses of methiamazole control hyperthyroidism better and lead to lower toxicity in comparison to thionamides, pregnancy is the exception condition for using methiamazole. Application of methimazole might lead to some neonatal undesirable outcomes with low prevalence including aplasia cutis (scalp lesions), choanal atresia (blocked nasal passage), and oesophageal atresia. Although thionamides may cause maternal liver injury and hepatic related complications, it is the preferred medication (a first-line agent) for managing the pregnant women hyperthyroidism specifically at the first trimester (14). Administering the antithyroid drugs has been recommended to be as low dose as possible. Overutilization should be avoided due to the potential risks of hypothyroidism and some long-term effects in fetus.

Hypothyroidism
Hypothyroidism (overt or subclinical types) can be observed among the pregnant women with the incidence rate of 3% to 5% of general population.
Low level of free thyroxine hormone accompanying with increased TSH is defined as overt hypothyroidism whereas normal level of thyroid hormone and high TSH can be explained as sub-clinical hypothyroidism. The situation with normal free thyroxine level and decreased TSH can be defined as isolated maternal hypothyroxinaemia. The general presentations of hypothyroidism might be increased weight, constipation, weakness, muscle cramps, cold intolerance, and dry skin. Iodine deficiency with the prevalence of 2 billion people is known as a major cause of hypothyroidism specifically in Central and South America and Asia (15). Thyroid peroxidase antibody (TPOAb) and thyroglobulin antibody (TgAb) are two types of antithyroid autoantibodies that rise in concentration during pregnancy in the first trimester of almost 18% of pregnancies. These autoantibodies can lead to hypothyroidism and other consequent disorders by affecting the thyroid such as spontaneous abortion, premature birth, infertility, maternal depression, or thyroiditis after delivery (15, 16). Thyroid autoimmunity is one of the major causes of hypothyroidism. Therefore, normal functioning of the endocrine and immune system is essential for maturation of oocytes and preventing the infertility and reproductive complications.
 According to several previous retrospective studies since 1993, various factors have been mentioned as consequences of undiagnosed or untreated hypothyroidism including abortion, hypertension, anemia, placental abruption, haemorrhage after delivery, several neonatal complications, requirement of the intensive care unit, and various fetal neurodevelopmental disorders (17-20)
A considerable reduction in the incidence of fetal neurodevelopmental disorders has been reported due to an appropriate diagnosis and controlling of convert or subclinical hypothyroidism of pregnant women (21). Because of the principal effect of iodine deficiency in occurrence of hypothyroidism and consequent cretinism, application of iodized salt, bread, water, and oil as iodine supplementation might be able to control iodine deficiency-induced disorders. Increased thyroxine intake has been proposed to be beneficial during pregnancy in iodine-sufficient conditions to treat hypothyroidism. Administering selenium during pregnancy has been suggested to be influential in decreasing the possibility of hypothyroidism incidence.
Detailed information of two clinical trials, which studied the efficacy of different treatment applied for reducing the hypothyroidism rate during pregnancy, is summarized in Table 1. These trials evaluated the incidence of pre-eclampsia and preterm delivery as the primary outcomes. Changes of the gestational hypertension, serum TSH and free T4, miscarriages, abruption, and clinical characteristics of newborns were considered as secondary outcomes of these trials.
Negro et al, in 2006, compared the efficacy of different levothyroxine (LT) doses on managing the thyroid function of TPOAb-positive pregnant women, with no intervention during pregnancy. According to Negro et al, using LT for TPOAb(+) pregnant women, only resulted in significant reduction of preterm labor and did not decrease the incidence of preeclampsia (21). In another clinical trial by Negro et al in 2007, the efficacy of selenium (Se) supplementation on reducing pregnancy complications and postpartum thyroid dysfunction was compared for the first time with placebo. In this study, not only no significant reductions were observed in preterm labor and pre-eclampsia rates as primary outcomes, but also the incidence of miscarriage did not decreased significantly using Se (22). According to two mentioned studies of Negro et al, application of LT or Se would not lead to significant reduction of pre-eclampsia in TPOAb-positive pregnant women. It can be also concluded that application of LT might be able to reduce the rate of preterm labor in TPOAb-positive pregnancies unlike the application of Se.
According to the study of Negro et al in 2007, postpartum thyroid dysfunction can be decreased significantly (RR 0.59; 95% CI 0.38 to 0.90)-(RD -0.20; 95% CI -0.35 to -0.05) by using Se supplementation for TPOAb-positive pregnant women (22).
In both of the studies of Negro et al by using LT or Se, significant reduction was only observed in miscarriage rate and no significant reduction was revealed in gestational hypertension or placental abruption as the secondary outcomes.
The efficacy of pre-pregnancy LT therapy in hypothyroidism cases to reduce the gestational complications during pregnancy was also evaluated in one prospective study (23). In this study, preconception suppressive LT therapy in hypothyroidism cases was considered to be effective in thyroid function during pregnancy, which was similar to the results obtained by Negro et al in 2006 (23). Initiating the application of increased doses of LT before the 11 weeks of gestation would significantly decrease the possibility of maternal hypothyroidism and further complications (24).
In conclusion, although iodine deficiency and thyroid disorders are among the public health dilemmas, there are not adequate country-based epidemiological studies about the prevalence of thyroid dysfunction. Although LT and Se are two common treatments in women with hypothyroidism anticipating pregnancy, further trials are needed to establish the efficacy of these treatment effects on improving the pregnancy outcomes.
 
Acknowledgement
We would like to thank Clinical Research Development Center of Ghaem Hospital for their assistant in this manuscript. This study was supported by a grant from the Vice Chancellor for Research of the Mashhad University of Medical Sciences for the research project as a medical student thesis with approval number of 911247.

 Conflict of Interest
The authors declare no conflict of interest.

  1. Stagnaro-Green A, Pearce E. Thyroid disorders in pregnancy. Nat Rev Endocrinol. 2012;8:650-658.
  2. Yazbeck CF, Sullivan SD. Thyroid disorders during pregnancy. Med Clin North Am. 2012;96:235-256.
  3. Krassas GE, Poppe K, Glinoer D. Thyroid function and human reproductive health. Endocr Rev. 2010;31:702-755.
  4. Vaidya B, Anthony S, Bilous M, et al. Detection of thyroid dysfunction in early pregnancy: Universal screening or targeted high-risk case finding? J Clin Endocrinol Metab. 2007;92:203-207.
  5. Mandel SJ. Hypothyroidism and chronic autoimmune thyroiditis in the pregnant state: maternal aspects. Best Pract Res Clin Endocrinol Metab. 2004;18:213-224.
  6. Allan WC, Haddow JE, Palomaki GE, et al. Maternal thyroid deficiency and pregnancy complications: implications for population screening. J Med Screen. 2000;7:127-130.
  7. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society Clinical Practice Guideline. Thyroid. 2007;17:1159-1167.
  8. Abraham P, Avenell A, Watson WA, et al. Antithyroid drug regimen for treating Graves’ hyperthyroidism. Cochrane Database Syst Rev. 2005:CD003420.
  9. Marx H, Amin P, Lazarus JH. Hyperthyroidism and pregnancy. BMJ. 2008;336:663-667.
  10. Palmieri C, Fisher RA, Sebire NJ, et al. Placental-site trophoblastic tumour: an unusual presentation with bilateral ovarian involvement. Lancet Oncol. 2005;6:59-61.
  11. Mestman JH. Hyperthyroidism in pregnancy. Best Pract Res Clin Endocrinol Metab. 2004;18:267-288.
  12. Watson WS, Balon HR, Meier DA, et al. Radioiodine therapy and pregnancy. J Nucl Med. 2005;46:1408-1409.
  13. Cooper DS. Antithyroid drugs. N Engl J Med. 2005;352:905-917.
  14. Abalovich M, Amino N, Barbour LA, et al. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2007;92:S1-47.
  15. Lazarus JH. Thyroid disorders associated with pregnancy: etiology, diagnosis, and management. Treat Endocrinol. 2005;4:31-41.
  16. McElduff A, Morris J. Thyroid function tests and thyroid autoantibodies in an unselected population of women undergoing first trimester screening for aneuploidy. Aust N Z J Obstet Gynaecol. 2008;48:478-480.
  17. Casey BM, Leveno KJ. Thyroid disease in pregnancy. Obstet Gynecol. 2006;108:1283-1292.
  18. Casey BM, Dashe JS, Spong CY, et al. Perinatal significance of isolated maternal hypothyroxinemia identified in the first half of pregnancy. Obstet Gynecol. 2007;109:1129-1135.
  19. Davis LE, Leveno KJ, Cunningham FG. Hypothyroidism complicating pregnancy. Obstet Gynecol. 1988;72:108-112.
  20. Leung AS, Millar LK, Koonings PP, et al. Perinatal outcome in hypothyroid pregnancies. Obstet Gynecol. 1993;81:349-353.
  21. Negro R, Formoso G, Mangieri T, et al. Levothyroxine treatment in euthyroid pregnant women with autoimmune thyroid disease: effects on obstetrical complications. J Clin Endocrinol Metab. 2006;91:2587-2591.
  22. Negro R, Greco G, Mangieri T, et al. The influence of selenium supplementation on postpartum thyroid status in pregnant women with thyroid peroxidase autoantibodies. J Clin Endocrinol Metab. 2007;92:1263-1268.
  23. Rotondi M, Mazziotti G, Sorvillo F, et al. Effects of increased thyroxine dosage pre-conception on thyroid function during early pregnancy. Eur J Endocrinol. 2004;151:695-700.
  24. Yassa L, Marqusee E, Fawcett R, et al. Thyroid hormone early adjustment in pregnancy (the THERAPY) trial. J Clin Endocrinol Metab. 2010;95:3234-3241.